

SYDNEY CANCER CONFERENCE 2016

THURSDAY, 22 SEPTEMBER 2016

Day 1					
Session 1 Theatre					
Chairs - A/Professor Anne Cust & Dr Kellie Charles					
8.30am	Opening addresses by Professor David Currow and Welcome to Country				
9.10am	Overview of CINSW Translational Cancer Research Centres Professor Paul De Souza, Professor Stephen Ackland, Professor John Simes, A/Professor Alexander Engel, Professor Paul Harnett, A/Professor Claire Wakefield & Professor David Goldstein				
10.00am	Keynote - Professor Caroline Dive, Cancer Research UK Manchester Institute <i>Circulating tumour cells in lung cancer, what are they good for?</i>				
11.00am	MORNING TEA				
Session 2		Cancer biology		Clinical research	
		Theatre		Room 6B	
		Chair - Dr Angelica Merlot		Chair - Professor Alan Boddy	
				Chair - A/Professor Claire Vajdic	
11.20am	A/Professor Guillaume Lessene Walter & Eliza Hall Institute <i>Targeting the BCL2 family proteins to treat cancer: challenges, successes and future perspectives</i>	11.20am	A/Professor Phil Darcy Peter MacCallum Cancer Centre	11.20am	Professor Peter O'Leary Curtin University <i>Personalised genomic risk stratification screening for cancer</i>
11.45am	Dr Darren Saunders Garvan Institute of Medical Research <i>Metabolic adaptation and stromal remodelling in pancreatic cancer: genotype-phenotype relationships</i>	11.45am	Professor Marie Ranson The University of Wollongong <i>A Phase 1 Study Of Deflexifol: a novel formulation of 5-fluorouracil with improved tolerability profiles</i>	11.45am	Dr Jacqueline Savard The University of Sydney <i>Ethical complexity: communicating genomic risk information in cancer prevention, screening and treatment</i>
12.10pm	A/Professor Geraldine O'Neill The University of Sydney <i>Differential response of patient-derived primary glioblastoma cells to tissue stiffness</i>	12.10pm	Professor Jen Martin The University of Newcastle <i>Putting the clinical pharmacology into interpretation of clinical trial data</i>	12.10pm	Professor Phyllis Butow The University of Sydney <i>Cancer Genomics: Psychosocial, behavioural and ethical issues and outcomes</i>
12.35pm	Mr Andrej Despotovski Asbestos Diseases Research Institute <i>Comparing tumour suppressing activity of microRNA mimics in malignant pleural mesothelioma</i>	12.35pm	Professor Paul De Souza Western Sydney University	12.35pm	Prof Mark Jenkins The University of Melbourne <i>Colorectal cancer risk prediction using family history and 45 independent risk-associated SNPs</i>
12.50pm	Dr Pei Liu Children's Cancer Institute Australia <i>Inhibition of a novel long noncoding RNA Rp1x In neuroblastoma results in complete tumor regression</i>			12.50pm	Prof Nehmat Houssami The University of Sydney <i>Prospective trial of tomosynthesis versus ultrasound for women with mammography-negative dense breasts</i>
1.05pm	Mr Jay Ryan Perry The University of Wollongong <i>Skin Deep: understanding metastatic non-melanoma skin cancer</i>	1.00pm	Dr Sarah-Jane Schramm The University of Sydney <i>Imago: enhancing multidisciplinary team care through knowledge transfer</i>	1.05pm	Dr Natalie Taylor Macquarie University <i>Using behaviour change and implementation science to translate hereditary cancer evidence into practice</i>

SYDNEY CANCER CONFERENCE 2016		
Day 1		
THURSDAY, 22 SEPTEMBER 2016		
1.20pm		
LUNCH AND POSTER VIEWING		
Session 3 Theatre		
Chair - A/Professor Anne Cust		
2.15pm	Keynote - Professor Colleen McBride, Emory University <i>Genomics' Value for Health Promotion: Fostering (b)reakthroughs</i>	
3.15pm	Plenary - Professor Leslie Burnett, Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research <i>The rapidly emerging role of Whole Genome Sequencing in clinical diagnostics</i>	
3.45pm	Community representative - Alex Carmichael	
4.00pm	Overview of translational research workshop agenda	
4.10pm		
AFTERNOON TEA		
Session 4		
TRANSLATIONAL RESEARCH WORKSHOP		
4.30pm		
Three breakout groups to discuss the challenges for translational cancer research		
Panel 1 – Biomedical/Clinical Research	Panel 2 – Biomedical/Clinical Research	Panel 3 – Clinical/Public Health/Psychosocial Research
Room 6A	Room 6B	Room 9A/B
Moderator - Dr Kellie Charles	Moderator - Dr Lenka Munoz	Moderators: A/Professor Claire Vajdic & A/Professor Anne Cust
Panelists	Panelists	Panelists
Professor Caroline Dive Cancer Research UK Manchester Institute	Professor Carlos Caldas Cancer Research UK Cambridge Institute	Professor Colleen McBride Emory University
Professor Ian Tannock University of Toronto	Professor Costas Kourmenis The University of Pennsylvania	Dr Pete Kelly The University of Wollongong
Professor Anna DeFazio The University of Sydney	Professor Jen Martin The University of Newcastle	Professor Leslie Burnett Garvan Institute of Medical Research
Dr Alan Taylor Clarity Pharmaceuticals	A/Professor Guillame Lessene Walter & Eliza Hall Institute of Medical Research	Professor Karen Canfell Cancer Council NSW
Ms Sally Crossing Cancer Voices NSW	Ms Robyn Leonard Consumer Representative	Professor Christine Paul The University of Newcastle
		Dr Carmen Huckel Schneider The University of Sydney
		Mr Alex Carmichael Community Representative
6.00pm -		
8.00pm		
CONFERENCE SOCIAL EVENT AND POSTER VIEWING		

SYDNEY CANCER CONFERENCE 2016					
Day 2					
FRIDAY, 23 SEPTEMBER 2016					
Session 5 Theatre					
Chairs - Dr Kellie Charles & A/Professor Georgina Long					
8.30am	Summary of findings from the translational research workshop				
9.00am	Keynote - Professor Carlos Caldas, Cancer Research UK Cambridge Institute <i>Breast cancer: characterizing, monitoring and modelling inter-and intra-tumour heterogeneity</i>				
10.00am	Plenary - Professor Helen Rizos, Macquarie University <i>Determinants of response and resistance in melanoma</i>				
10.30am MORNING TEA					
Session 6		Experimental therapies		Clinical biomarkers	
Theatre		Room 6A		Quality of life and survivorship	
Chair - Dr Tao Liu		Chair - Professor Helen Rizos		Chair - Professor Phyllis Butow & Dr Claudia Rutherford	
11.00am	Professor Ricky Johnstone Peter MacCallum Cancer Centre <i>Advanced anti-cancer responses through functional interplay between epigenetic- and immuno-therapies</i>	11.00am	Dr Stacy Edwards QJMR Berghofer <i>Beyond GWAS: Illuminating the dark road from association to function</i>	11.00am	Professor Penny Schofield Peter MacCallum Cancer Centre <i>Development of Navigate: an online treatment decision aid for men diagnosed with low risk prostate cancer</i>
11.25am	Dr Marina Paijic Garvan Institute of Medical Research <i>Personalised medicine in pancreatic cancer: drug resistance, new insights and therapeutic opportunities</i>	11.25am	Professor Graham Mann The University of Sydney <i>The whole genome mutation landscape of melanoma</i>	11.25am	A/Professor Claire Wakefield UNSW Australia <i>Genetics services in childhood cancer: What does the future hold?</i>
11.50am	Professor Minoti Apte UNSW Australia <i>Novel therapeutic approaches targeting the stroma of pancreatic cancer</i>	11.50am	A/Professor Kevin Spring Western Sydney University <i>Expression profiling of circulating miRNA during neoadjuvant chemoradiation therapy for locally advanced rectal cancer</i>	11.50am	A/Professor Kerry Sherman Macquarie University <i>Self-compassionately viewing my body after cancer</i>
12.15pm	Dr Wei Deng Macquarie University <i>PLAG nanocomposites loaded with verteporfin and gold nanoparticles for enhanced photodynamic therapy</i>	12.15pm	Mr Anton Kalsbeek Garvan Institute of Medical Research <i>Mutation load of mitochondrial genome predicts pathology and biochemical recurrence in prostate cancer</i>	12.15pm	Prof Madeleine King The University of Sydney <i>Cancer-specific quality of life (QOL) measures for economic evaluation: the EORTC QLQ-UC10D and FACT-8D</i>
Findings from recent fear of cancer recurrence RCTs:					
12.30pm	Dr Chenchen Jiang The University of Newcastle <i>Class I histone deacetylase control the expression of PD-L1 in melanoma</i>	12.30pm	Dr Su Yin Lim Macquarie University <i>Identification of plasma biomarkers to predict response to combined immunotherapy in melanoma</i>	12.30pm	Ms Stephanie Tesson The University of Sydney <i>A randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence</i>
12.45pm	A/Prof Georgina Clark ANZAC Research Institute <i>Therapeutic antibodies targeting acute myeloid leukaemia</i>	12.45pm	Dr Christoph Krisp Macquarie University <i>Patient-derived melanoma cancer cell line MEK inhibitor response proteotypes predict patient outcome</i>	12.40pm	Ms Mbathio Dieng The University of Sydney <i>Effectiveness of a psycho-educational intervention to reduce fear of cancer recurrence in melanoma patients</i>
				12:50pm	Audience & Panel Discussion

SYDNEY CANCER CONFERENCE 2016					
Day 2					
FRIDAY, 23 SEPTEMBER 2016					
1.00pm LUNCH AND POSTER VIEWING					
Session 7		T1 to T2 research		Imaging & radiotherapy	
Theatre		Room 6B		Behavioural approaches, at-risk population groups	
Chair - Dr Lenka Munoz		Chair - Dr Dinny Graham		Chair - A/Professor Ilona Juraskova	
1.45pm	Professor Constantino Koumenis University of Pennsylvania <i>The unfolded protein response in tumor progression and metastasis: problems and opportunities for therapeutic intervention</i>	1.45pm	Professor Pam Russell Queensland University of Technology <i>New PSMA targeted approaches for imaging and therapy of prostate cancer</i>	1.45pm	Professor Elizabeth Eakin The University of Queensland <i>Promoting healthy living after cancer</i>
2:10pm	Dr Luke Hesson UNSW Australia <i>Integrated genetic, epigenetic and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumours</i>	2:10pm	Professor Anatoly Rozenfeld The University of Wollongong <i>Safe delivery of radiotherapy is priority</i>	2:10pm	Professor Rob Sanson-Fisher The University of Newcastle <i>Patient centred care: it's time to provide the rigour and focus it deserves</i>
2:35pm	Professor Hubert Hondermarck The University of Newcastle <i>Nerve infiltration in the tumour microenvironment: a novel promoter of cancer progression</i>	2:35pm	Professor Paul Keall The University of Sydney <i>Targeted radiotherapy: current trends and future directions</i>	2:35pm	Dr Peter Kelly The University of Wollongong <i>Improving the health behaviours of people living with mental illness</i>
3:00pm	Mr David Lynch Western Sydney University <i>The isolation of CTCs from glioma patients</i>	3:00pm	Prof Gerald Fogarty St Vincent's Hospital <i>Five high quality Australian trials are helping define the role of radiotherapy in melanoma</i>	3:00pm	Dr Kathy Flitcroft The University of Sydney <i>Equity implications of uncoordinated health data collection systems: The case of breast reconstruction</i>
3:15pm	Dr Li Li Ochsner Clinic Foundation, USA & The University of Queensland <i>Lymph node stromal microenvironment and cancer metastasis</i>	3:15pm	Dr Jesmin Shafiq UNSW Australia <i>A population-based model of local control and survival benefit of radiotherapy for breast cancer</i>	3:15pm	Dr Maarit Laaksonen UNSW Australia <i>Burden of lung cancer attributable to lifestyle risk factors: pooled study of seven Australian cohorts</i>
3:30pm	Dr David Simar UNSW Australia <i>Accelerated epigenetic aging in childhood cancer survivors</i>	3:30pm	Dr Elizabeth New The University of Sydney <i>Fluorescent sensors for studying the oxidative capacity and metal ion status of cancer cells</i>	3:30pm	Prof Dianne O'Connell Cancer Council NSW <i>Hospital-based care at the end of life for Aboriginal people dying from cancer in New South Wales</i>
3.45pm AFTERNOON TEA					

SYDNEY CANCER CONFERENCE 2016		
FRIDAY, 23 SEPTEMBER 2016		
Day 2		
Session 8		
4.05 - 4.50pm		
Basic & clinical research Theatre	Basic & clinical research Room 6A	Public health & psychosocial research Room 6B
Chairs - Dr Kara Perrow & Dr Kamila Marzec	Chairs - Professor Marie Ranson & Dr Jenny Wang	Chairs - Professor Madeleine King & A/Professor Kerry Sherman
Mr Arutha Kulasinghe Queensland University of Technology <i>Could precision medicine be tailor-made for metastatic head and neck cancer</i>	Dr Jennifer Hsu The University of Melbourne <i>Therapeutic blood dendritic cell vaccination: arming the immune system to fight cancer</i>	Ms Zoe Loh The University of Melbourne <i>Routine blood investigations have no utility in the follow-up of aggressive lymphomas</i>
Dr Sarah Hayes The University of Sydney <i>Swath-ms profiling of NSCLC cell lines: defining mechanisms of erlotinib resistance</i>	Dr Chun-Chien (Andy) Shieh The University of Sydney <i>Direct tumour tracking during lung radiotherapy</i>	Ms Janine Vetsch Kids Cancer Centre, Sydney Children's Hospital <i>Long-term childhood cancer survivors' and parents' information needs</i>
Ms Athena Phoa The University of Sydney <i>Pharmacology of novel small-molecule tubulin inhibitors for glioblastoma</i>	Ms Lauren Touyz Kids Cancer Centre, Sydney Children's Hospital <i>Glucocorticoids and body mass index in childhood acute lymphoblastic leukemia</i>	A/Professor Ilona Juraskova The University of Sydney <i>Delphi consensus evaluation of strategies for oncology clinicians communicating with family carers</i>
Dr Zaklina Kovacevi The University of Sydney <i>Targeting the potent metastasis suppressor, NDRG1, for the treatment of aggressive breast cancer</i>	Mrs Ann-Katrin Piper The University of Sydney <i>Myoferlin cleavage increases Erk phosphorylation</i>	Ms Amelia Smit The University of Sydney <i>The impact of delivering personalised genomic risk of melanoma: A pilot randomised controlled trial</i>
Ms Lisa Belfiore The University of Wollongong <i>Development of dual-targeted drug-loaded liposomes to treat uPAR/HER2-positive metastatic breast cancer</i>	Dr Camilla Mitchell Kids Research Institute, The Children's Hospital at Westmead <i>Matrix-metalloproteinase-mediated cooperative cell invasion</i>	Dr Felicia Roncolato NHMRC Clinical Trials Centre <i>Baseline QOL as a predictor of stopping chemotherapy early, and survival, in ovarian cancer</i>
Dr Yuen Yee Cheng Asbestos Diseases Research Institute <i>Investigating the role of microRNAs in drug resistance of mesothelioma cells using a 3D spheroid model</i>	Ms Kellie Toohey The University of Canberra <i>Effects of exercise intensity on cardiovascular risk factors in cancer</i>	Mr Alistair Lum Kids Cancer Centre, Sydney Children's Hospital <i>Adding childhood cancer treatment to school: accounting for the social and personal implications</i>
Dr Pei Ni Ding Western Sydney University <i>Blood based testing in the treatment monitoring for EGFR mutated non-small cell lung cancer</i>	Ms Heloisa Milioli The University of Newcastle <i>Basal-like breast cancers uncovered by genomic and transcriptomic profiles and patients' overall survival</i>	Ms Tong Li The University of Sydney <i>Variations of mammographic density in urban China: associated agents and potential implications</i>
Ms Emily Chan The University of Melbourne <i>Momelotinib improves the efficacy of chemotherapy treatment and tumour burden in ovarian cancer</i>	Ms Diana Shinko The University of Sydney <i>Investigation of immune complexity in cancer patients using mass cytometry</i>	Dr Brigid Lynch The University of Melbourne <i>DNA methylation age of blood and the risk of common cancers: a pooled analysis of six prospective studies</i>
Dr Helen McGuire Centenary Institute <i>Using mass cytometry to profile immune signatures for cancer immunotherapy</i>	Mr Joseph Po Western Sydney University <i>Epithelial to mesenchymal transition phenotype CTC enrichment in advanced ovarian cancer patients</i>	Ms Sarah Ellis Kids Cancer Centre, Sydney Children's Hospital <i>Evaluation of 'Cascade': online support for parents following their child's cancer treatment</i>
Mr Mouhamad Reslan The University of Sydney <i>Development of a trastuzumab (Herceptin(R)) biobetter with enhanced stability and binding affinity to HER2</i>	Dr Zelong Lim The University of Sydney <i>Fluorescent tools to study platinum</i>	
4.50pm Theatre	Closing Remarks & Awards	
Chairs - A/Professor Anne Cust & Dr Kellie Charles		
5.00pm	CLOSE DAY 2	